Stock listing

Rezolute, Inc.

Selected listing: A2QEWP · LS · EUR · DE

Rezolute, Inc. (Lang & Schwarz: A2QEWP), Health Technology. Latest release Oct 5, 2026: Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting…

A2QEWP:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2QEWP
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

About Rezolute, Inc.

Rezolute, Inc. (RZLT) is listed on 6ix with investor news, events, company updates, and market data in one place. Follow the company page to track new releases, upcoming presentations, and the latest information available on 6ix.

Latest news from Rezolute, Inc.

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

October 4, 2026

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

October 5, 2026

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

September 24, 2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

September 9, 2026

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

June 17, 2026

All Rezolute, Inc. news →

Research Rezolute, Inc.

Rezolute, Inc. company profile

View the public company page for Rezolute, Inc. on 6ix.

Rezolute, Inc. news

Read company news and market updates connected to Rezolute, Inc..

Rezolute, Inc. investor events

Find investor webinars, events, and replay context for Rezolute, Inc..